Clinical Edge Journal Scan

Is iatrogenic tumor seeding a risk factor for metachronous CRC? Evidence suggests otherwise


 

Key clinical point: The association between metachronous colorectal cancer (CRC) diagnosis and biopsy of nontumor sites after biopsy of an initial CRC in the same colonoscopy is not significant.

Major finding: Nontumor site biopsy after initial CRC biopsy was not significantly associated with the risk for metachronous CRC in the colonic segment of the additional biopsy site (adjusted odds ratio 2.29; 95% CI 0.77-6.81).

Study details: This retrospective case-control study included 45 adult patients, diagnosed with CRC by colonoscopy with biopsy who underwent complete curative resection and were re-diagnosed with CRC within 6 months to 4 years of the initial diagnosis, and 212 matched control individuals.

Disclosures: The study was supported by the Population-based Research to Optimize the Screening Process Consortium, US National Cancer Institute. The authors declared no conflicts of interest.

Source: Lam AY et al. Biopsy of non-tumor sites after biopsy of a colorectal cancer is not associated with metachronous cancers: a case-control study. Clin Gastroenterol Hepatol. 2022 (May 26). Doi: 10.1016/j.cgh.2022.05.006

Recommended Reading

Panitumumab beats bevacizumab in left-sided mCRC
MDedge Hematology and Oncology
‘Great optimism’ greets immunotherapy responses in dMMR rectal cancer
MDedge Hematology and Oncology
Esophageal cancer screening isn’t for everyone: Study
MDedge Hematology and Oncology
At-home colorectal cancer testing and follow-up vary by ethnicity
MDedge Hematology and Oncology
AGA issues position statements on reducing CRC burden
MDedge Hematology and Oncology
AI-based CADe outperforms high-definition white light in colonoscopy
MDedge Hematology and Oncology
New treatment reduces risk of anal cancer in people with HIV
MDedge Hematology and Oncology
Intensified chemotherapy confers no additional benefits with panitumumab in RAS and BRAF wt mCRC
MDedge Hematology and Oncology
Atezolizumab added to FOLFOXIRI + bevacizumab seems safe and beneficial in previously untreated mCRC
MDedge Hematology and Oncology
Therapy trends in patients with mCRC after the second disease progression
MDedge Hematology and Oncology